Journal of Hematology & Oncology 2021

5 papers
The 2021 edition of the Journal of Hematology & Oncology emphasized the development of targeted therapies and the management of treatment resistance. Research themes included the use of micellar delivery systems for CD123-targeted peptides in treating refractory acute myeloid leukemia and phase 2 clinical evaluations of geptanolimab for peripheral T-cell lymphoma. Prolific authors such as Jianxiang Wang and Tao Wen contributed to work exploring competitive antagonism of signaling receptors and strategies to overcome proteolytic degradation in peptide drug design. Epidemiological and genomic analyses also formed a core component of the year’s publications. Studies examined the global burden of cancer in adolescents and young adults across 204 countries and reclassified BRCA1 and BRCA2 variants within large Chinese breast cancer cohorts. Additionally, proteogenomic research investigated metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma. These efforts reflect a broader trend toward integrating population-level data with molecular insights to address gaps in preclinical immunotherapy and post-acute recovery.

Top Research Directions

The 12 research directions with Journal of Hematology & Oncology 2021 papers, ranked by paper count. Share is the fraction of the edition’s papers in the direction.

#DirectionPapersShare
1Causal Attribution Challenges in Single Arm Trials120.0%
2Demographic Normalization in Epidemiological Analysis120.0%
3Evaluating the Global Generalizability of Localized Clinical Cohorts120.0%
4Molecular Mechanisms of Sex Differences in Cancer120.0%
5Quantifying the Total Burden of Disease120.0%
6Quantifying the True Burden of Non Fatal Health Conditions120.0%
7Restricted Cubic Splines for Non-Linear Risk Modeling120.0%
8Reversing T Cell Anergy with Immune Checkpoint Blockade120.0%
9Standardized Frameworks for Tumor Response Assessment120.0%
10The Mismatch Between Disease Detection and Treatment Capacity120.0%
11The Predictive Biomarker Bottleneck in Personalized Medicine120.0%
12The Sustainability Gap in Short-Term Clinical Evaluations120.0%

Download all directions as CSV

Institutions

Institutions credited by Journal of Hematology & Oncology 2021 papers: a paper credits every institution named in its affiliations, once. 14 institutions share 4 credited papers.

#InstitutionPapersShare
1Chinese Academy of Medical Sciences & Peking Union Medical College 250.0%
20093mkr06 125.0%
304n16t016 125.0%
4053qy4437 125.0%
5Academia Sinica 125.0%
6Cancer Hospital of Chinese Academy of Medical Sciences 125.0%
7Capital Medical University 125.0%
8Chinese Academy of Sciences 125.0%
9Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences 125.0%
10National Center for Nanoscience and Technology 125.0%
11Shanghai First People's Hospital 125.0%
12Shanghai Jiao Tong University 125.0%
13University of Hong Kong 125.0%
14Zhejiang University 125.0%

Download all institutions as CSV

About this data

Papers. Journal of Hematology & Oncology 2021 lists 5 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 4 of 5 papers (80.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-17 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of Hematology & Oncology 2021”, https://lacuna.tiptreesystems.com/venue/journal-of-hematology-oncology/2021.

Top Authors

AuthorPapers
Guosheng Yin1

Impactful Papers

Papers from Journal of Hematology & Oncology 2021 that shaped research clusters.

Foundational

Influential

Papers

Title
A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)
Integrated proteogenomic analysis revealed the metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma
Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohort
The global, regional, and national burden of cancer among adolescents and young adults in 204 countries and territories, 1990–2019: a population-based study